1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,108 | 0,175 | 05.12. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | QLife Holding AB: Qlife's Birmingham PKU clinical trial published with strong results - key milestone toward CE-mark submission and market launch | 56 | GlobeNewswire (Europe) | Qlife Holding AB ("Qlife" or the "Company") a first mover in clinical-grade home diagnostics, announces publication of the clinical study for PKU children and adolescents under 18 years of age. The... ► Artikel lesen | |
| 14.11. | QLife Holding AB: Update on the reverse takeover process - "Red Chip" structure will not be approved by Nasdaq - other structures are pursued | 212 | GlobeNewswire (Europe) | Qlife Holding AB ("Qlife" or "the Company") and Hipro Biotechnology Co., Ltd. ("Hipro") are working on the planned reverse takeover, as announced in press releases on 5 June 2025 and 5 October 2025.... ► Artikel lesen | |
| 12.11. | Qlife Holding AB Q3 Sales Decline | 1 | RTTNews | ||
| 12.11. | QLife Holding AB: QLIFE HOLDING AB, Interim Report Q3, July - September 2025 | 102 | GlobeNewswire (Europe) | Advancing Integration & Innovation: Building a Diagnostics Powerhouse
The full report is attached and can also be found here: https://qlifeholding.com/en/investors/finansiella-rapporter
Financial summary... ► Artikel lesen | |
| 05.10. | QLife Holding AB: The Letter of Intent with Hipro Biotechnology Co., Ltd. regarding reverse takeover has been extended | 79 | GlobeNewswire (Europe) | Qlife Holding AB ("Qlife" or the "Company") announces an extension of the Letter of Intent regarding a potential reverse takeover (the "Transaction") with Hipro Biotechnology Co., Ltd. ("Hipro"). The... ► Artikel lesen | |
| 22.09. | Qlife Holding AB announces the outcome of the exercise of warrants series TO 6 | 1 | Cision News | ||
| QLIFE Aktie jetzt für 0€ handeln | |||||
| 15.09. | QLife Holding AB: Qlife announces additional product line and progresses two new tests into clinical trials | 127 | GlobeNewswire (Europe) | Qlife, a first mover in clinical-grade home diagnostics, and its partner Hipro Biotechnology are advancing two additional biomarker tests-nt-proBNP and potassium-into clinical trials targeting Congestive... ► Artikel lesen | |
| 27.08. | QLife Holding AB: QLIFE HOLDING AB, Interim Report Q2, April to June 2025 | 193 | GlobeNewswire (Europe) | Towards a merger with a vision
The full report is attached and can also be found here: https://qlifeholding.com/en/investors/finansiella-rapporter
Financial summary - second quarter 2025
Revenue... ► Artikel lesen | |
| 27.08. | QLife Holding AB: Progress update on the reverse takeover process between Qlife and Hipro | 144 | GlobeNewswire (Europe) | Gothenburg, Sweden - Qlife Holding AB ("Qlife" or the "Company") and Hipro Biotechnology Co., Ltd. ("Hipro") remain fully committed to completing the transaction announced in the Letter of Intent signed... ► Artikel lesen | |
| 21.08. | Qlife Holding AB increases existing credit facility and extends the maturity date | 1 | Cision News | ||
| 21.08. | QLIFE HOLDING AB: Qlife together with Birmingham Women's and Children's NHS Foundation Trust achieve positive results for its rare disease self-test PHE product | 2 | Cision News | ||
| 09.07. | QLIFE HOLDING AB: Qlife resolves to carry out a directed set-off issue of approximately SEK 2.47 million in accordance with previously announced credit facility agreement | 1 | Cision News | ||
| 05.06. | Qlife Holding AB receives observation status | 243 | GlobeNewswire | Today, June 5, 2025, Qlife Holding AB (the "Company") issued a press release with information that it has entered into a letter of intent for a reverse takeover of Hipro Biotechnology Co., Ltd.,... ► Artikel lesen | |
| 05.06. | QLife Holding AB: Qlife enters letter of intent with Hipro Biotechnology Co., Ltd. to join forces through a reverse takeover | 237 | GlobeNewswire (Europe) | Qlife Holding AB ("Qlife" or the "Company") has entered into a non-binding letter of intent ("Letter of Intent") with Hipro Biotechnology Co., Ltd., registration no. 91130100794182204D, ("Hipro") regarding... ► Artikel lesen | |
| 28.05. | QLife Holding AB: Bulletin from the annual general meeting 2025 of Qlife Holding AB | 162 | GlobeNewswire (Europe) | Qlife Holding AB held its annual general meeting on 28 May 2025. At the meeting, the following resolutions were made.
The English text is an unofficial translation. In case of any discrepancies between... ► Artikel lesen | |
| 20.05. | QLife Holding AB: QLIFE HOLDING AB, Interim Report Q1, January to March 2025 | 319 | GlobeNewswire (Europe) | Progress on all levels
The full report is attached and can also be found here: https://qlifeholding.com/en/investors/finansiella-rapporter
Financial summary - first quarter 2025
Revenue in the... ► Artikel lesen | |
| 25.03. | QLife Holding AB: Qlife announces that it has received approval from UK authorities to initiate a clinical trial in the UK | 230 | GlobeNewswire (Europe) | The Egoo Phe System, developed to measure phenylalanine (Phe) levels associated with the PKU condition, is now entering its final phase ahead of initial registration in the UK and submission to a Notified... ► Artikel lesen | |
| 21.03. | QLife Holding AB: Bulletin from the extraordinary general meeting in Qlife Holding AB on 21 March 2025 | 271 | GlobeNewswire (Europe) | Today, on 21 March 2025, an extraordinary general meeting was held in Qlife Holding AB. A summary of the adopted resolutions follows below.
Election and remuneration of the board of directors
The... ► Artikel lesen | |
| 04.03. | The observation status for Qlife Holding AB is removed | 226 | GlobeNewswire | On February 13, 2024, Qlife Holding AB (the "Company") was given observation status with reference to material adverse uncertainty in respect of the issuer's financial position.
On February 26... ► Artikel lesen | |
| 26.02. | QLife Holding AB: Qlife announces outcome in rights issue | 334 | GlobeNewswire (Europe) | NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA... ► Artikel lesen |
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MOUNTAIN VALLEY MD | 0,001 | 0,00 % | Mountain Valley MD Holdings Inc: Mountain Valley appoints Batchelor as director | ||
| SIEMENS HEALTHINEERS | 43,510 | +1,92 % | EQS-PVR: Siemens Healthineers AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: Siemens Healthineers AG
Siemens Healthineers AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
01.12.2025 /... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 40,040 | +0,08 % | UBS stuft FMC FRESENIUS MEDICAL CARE AG auf 'Sell' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für FMC mit einem Kursziel von 38 Euro auf "Sell" belassen. Analyst Graham Doyle blieb in seiner Einschätzung vom Freitagabend... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 35,790 | +1,79 % | IPO Stock Of The Week: Health Care Leader BrightSpring Falls Back Into Buying Range | ||
| PROCEPT BIOROBOTICS | 35,860 | +1,21 % | PROCEPT BioRobotics Reports Third Quarter 2025 Financial Results and Issues 2026 Revenue Guidance | SAN JOSE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative... ► Artikel lesen | |
| FRESENIUS | 47,720 | -0,60 % | DZ BANK stuft Fresenius SE auf 'Kaufen' | FRANKFURT (dpa-AFX Analyser) - Die DZ Bank hat den fairen Aktienwert für Fresenius nach den Anfang November vorgelegten Zahlen zum dritten Quartal von 56 auf 57 Euro angehoben. Die Einstufung wurde... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 19,550 | +0,77 % | Alignment Healthcare Reports Third Quarter 2025 Results, Surpasses High-End of Guidance Across All Key Metrics | Reports Q3 revenue of $993.7 million, up 43.5% year-over-yearBeats high end of third quarter guidance and raises full-year outlook across all key metrics: membership, revenue, adjusted gross profit... ► Artikel lesen | |
| GENEDX | 158,96 | -1,85 % | Cathie Wood's ARK sells Iridium, buys GeneDx and WeRide stock | ||
| PROGYNY | 24,020 | -0,54 % | Progyny, Inc. Announces Third Quarter 2025 Results | Reports Revenue of $313.3 Million, Reflecting 9.3% GrowthRaises Full Year Guidance to Reflect Continued Strength in Member EngagementSelling Season Yields Over 80 New Clients, 900,000 New Lives, and... ► Artikel lesen | |
| BETA BIONICS | 29,380 | -2,07 % | Beta Bionics, Inc.: Beta Bionics Reports Third Quarter 2025 Financial Results and Raises Full Year 2025 Guidance | IRVINE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial... ► Artikel lesen | |
| NUTEX HEALTH | 160,95 | +2,65 % | Nutex Health extends share repurchase plan | ||
| GERRESHEIMER | 25,860 | -1,52 % | Gold, Drohnen und Spezialglas! Einfach mal 200 % aus dem Stand mit DroneShield, AJN Resources und Gerresheimer | Die Börse zeigt sich von der volatilen Seite. Während KI-, Rüstungs- und Tech-Aktien auch mal konsolidieren, schießen Gold und Silber durch die Decke. Die Branchenrotation ist zum Jahresende also voll... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 43,440 | +0,32 % | EQS-PVR: Carl Zeiss Meditec AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution | EQS Voting Rights Announcement: Carl Zeiss Meditec AG
Carl Zeiss Meditec AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the... ► Artikel lesen | |
| AVEANNA HEALTHCARE | 9,310 | +1,92 % | Aveanna Healthcare stock price target raised to $13 by Raymond James | ||
| GOODRX | 2,710 | -1,45 % | HIMS vs. GDRX: Which Consumer Health Stock Offers Greater Upside? |
Das Unternehmen QLIFE HOLDING AB kann der Branche Gesundheitswesen zugeordnet werden. Die relative Kursveränderung beträgt aktuell -6,60 % bei einem Aktienkurs von 0,095 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu QLIFE HOLDING AB finden Sie auf Wallstreet Online.